Active Clinical Trials

Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.

Showing 181 results
  • Sort by
  • Study title
  • Condition
  • Phase
  • Location
Study title Condition Phase Location NCT ID

A Study to Investigate the Pharmacokinetics and Safety of PKN605 in Participants With Moderate and Severe Renal Impairment Compared to Matched Control Subjects With Normal Renal Function

 		Participants With Moderate and Severe Renal Impairment and Healthy Participants Phase1 United States NCT07797322

PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan

 		Metastatic Prostate Cancer Switzerland NCT07484269

Pluvicto Real-world Investigation in Survival in Metastatic CRPC

 		Prostatic Neoplasms, Castration-Resistant, Neoplasm Metastasis United States NCT07697989

A Study of the Safety and Effectiveness of Onasemnogene Abeparvovec (Zolgensma) Intrathecal Injection in Spinal Muscular Atrophy Patients

 		Spinal Muscular Atrophy Japan NCT07767890

A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates

 		Hypertension United Arab Emirates NCT07465666

A Study to Explore the Tissue Level Effects of Remibrutinib in Adults With Moderate to Severe HS

 		Hidradenitis Suppurativa Phase1 United States NCT07855276

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

 		Primary IgA Nephropathy Phase3 United States NCT04557462

Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks

 		Chronic Spontaneous Urticaria Phase3 Hong Kong
Japan
South Korea 		NCT07816328

A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period

 		VEXAS Syndrome Phase2 Japan NCT07748624

A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain

 		Complement 3 Glomerulopathy Spain NCT07598448